SCHEMBL5879244

SCHEMBL5879244

O=c1[nH]c(=O)c2c1c1[nH]c3ccc(F)cc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.59
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
CDC25A P30304 1/20 0.48
CDC25C P30307 1/20 0.48
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
FEN1 P39748 1/20 0.45
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
MPO P05164 1/20 0.43
METAP2 P50579 1/20 0.42
CDK4 P11802 2/20 0.42
CCND1 P24385 2/20 0.42
CCNE2 O96020 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879318 0.86 CHEK1 (0.59) CHEK1CDK5CDK5R1CDC25ACDC25C
SCHEMBL5879153 0.79 CHEK1 (0.59) CHEK1CDK4CCND1
SCHEMBL5879297 0.79 CHEK1 (0.59) CHEK1CDK5CDK5R1ALDH1A1LMNA
SCHEMBL5879303 0.79 CHEK1 (0.59) CHEK1CDC25ACDC25CKDM4EGAA
SCHEMBL5879181 0.79 CHEK1 (0.82) CHEK1KDM4EALDH1A1GLAGAA
SCHEMBL5879160 0.79 CHEK1 (0.82) CHEK1CDK5CDK5R1GAA
SCHEMBL5332887 0.79 CDK5 (0.46) CHEK1KEAP1NFE2L2CDK5CDK5R1
SCHEMBL13417447 0.76 KDM4E (0.65) KEAP1NFE2L2CDK5CDK5R1KDM4E
SCHEMBL5879238 0.76 PDGFRB (0.62) CHEK1KDM4EALDH1A1GAAHPGD
SCHEMBL22566960 0.75 CDK4 (0.71) CHEK1CDK5CDK5R1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885KEAP1 994/4885NFE2L2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.